Effects of PI3K Inhibition on Peripheral Leukocytes in Metastatic Breast Cancer

Hot off the Press.
Effects of PI3K Inhibition on Peripheral Leukocytes in Metastatic Breast Cancer
"The authors of this combined analysis of peripheral blood of patients enrolled in four clinical trials of PI3K inhibitors evaluated the effect of these medications on immune cells in this patient population. Patients who responded to treatment with PI3K inhibitors who had a positive fold change in T-cell population had a longer duration of treatment response (31.4 months) compared with those who responded to treatment but had a negative fold change in T cell population (5 months)".

"CONCLUSIONSThese results highlight the potential for PI3K inhibition to sensitize tumors to immune checkpoint inhibitors, thus providing additional therapeutic options for patients with MBC".

Truly remarkable results, how long before a new collaboration study commences with the combination of Paxalisib and immune checkpoint inhibitors

https://www.practiceupdate.com/c/104894/67/13/?elsca1=emc_enews_weekinreview&elsca2=email&elsca3=practiceupdate_metastaticbreastcancer&elsca4=metastaticbreastcancer&elsca5=newsletter&rid=NDQ3MTgxOTYwMzc4S0&lid=10332481

Regards.